Bagley, Mark Christopher, Davis, Terence ORCID: https://orcid.org/0000-0003-2780-0262, Rokicki, Michal Jaroslaw, Widdowson, Caroline Susan and Kipling, David Glyn 2010. Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome. Future Medicinal Chemistry 2 (2) , pp. 193-201. 10.4155/fmc.09.163 |
Abstract
Background: UR-13756 is a potent and selective p38 mitogen-activated protein kinase (MAPK) inhibitor, reported to have good bioavailability and pharmacokinetic properties and, thus, is of potential use in the treatment of accelerated aging in Werner syndrome. Results and discussion: Irradiation of 2-chloroacrylonitrile and methylhydrazine in ethanol at 100°C gives 1-methyl-3-aminopyrazole, which reacts with 4-fluorobenzaldehyde and a ketone, obtained by Claisen condensation of 4-picoline, in a Hantzsch-type 3-component hereocyclocondensation, to give the pyrazolopyridine UR-13756. UR-13756 shows p38 MAPK inhibitory activity in human telomerase reverse transcriptase-immortalized HCA2 dermal fibroblasts, with an IC50 of 80 nm, as shown by ELISA, is 100% efficacious for up to 24 h at 1.0μm and displays excellent kinase selectivity over the related stress-activated c-Jun kinases. In addition, UR-13756 is an effective p38 inhibitor at 1.0 μm in Werner syndrome cells, as shown by immunoblot. Conclusion: The convergent synthesis of UR-13756 is realized using microwave dielectric heating and provides a highly selective inhibitor that shows excellent selectivity for p38 MAPK over c-Jun N-terminal kinase.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Chemistry Medicine |
Subjects: | Q Science > QD Chemistry |
Publisher: | Future Science Ltd |
ISSN: | 1756-8919 |
Last Modified: | 14 Dec 2022 02:14 |
URI: | https://orca.cardiff.ac.uk/id/eprint/19631 |
Citation Data
Cited 19 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |